Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pexa-Vec plus Dewallumab vs Dewallumab in previously treated advanced melanoma
CTR20210605Phase 2Terminated
- Sponsor
- China Oncology Focus
- Start
- Apr 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of vaccinia granulocyte-macrophage colony-stimulating factor recombinant virus, socazolimab in melanoma, sponsored by China Oncology Focus. Started Apr 2021; status: terminated.
02
Drugs
vaccinia granulocyte-macrophage colony-stimulating factor recombinant virussocazolimab
03
Conditions
melanoma
Beyond the preview
Go deeper on CTR20210605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210605.